KINETA, INC.
Small-molecule RIG-I like receptor (RLR) agonists that activate dendritic cells and induce immunogenic cell death in cancer cells
New patent ·
- Sector
- Biotech
- Headquarters
- Seattle, WA
- Founded
- 2007
- Latest Form D
- $2.4M, Mar 2022
- Total capital
- $46M
- Federal grants
- $5.2M
- 7 awards · 2016–2020
- Rank in peer group#152 of 514
- Private capital raised
- $40.8M
- 19 Form D · last Mar 2022
- 56 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 9
- 31 pending · first 2015
- Rank in peer group#35 of 514
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 19th filing$2.4M
- Private capital raisedForm D · SEC · 18th filing$1.2M
- Private capital raisedForm D · SEC · 17th filing$10M
- Private capital raisedForm D · SEC · 16th filing$100K
- Federal grantHealth and Human S · Phase II · Small-molecule agonists of the RIG-I-like receptor pathway as cancer immunotherapeutics$750K
- Private capital raisedForm D · SEC · 15th filing$250K
- Private capital raisedForm D · SEC · 14th filing$45K
- Private capital raisedForm D · SEC · 13th filing$7.1M
- Private capital raisedForm D · SEC · 12th filing$192K
- Private capital raisedForm D · SEC · 11th filing$26K
- Offering registeredForm D · SEC · 10th filing$24.4M
- Private capital raisedForm D · SEC · 9th filing$9M
- Private capital raisedForm D · SEC · 8th filing$500K
- Private capital raisedForm D · SEC · 7th filing$5M
- Private capital raisedForm D · SEC · 6th filing$500K
- Private capital raisedForm D · SEC · 5th filing$47K
- Private capital raisedForm D · SEC · 4th filing$250K
- Private capital raisedForm D · SEC · 3rd filing$1.8M
- Private capital raisedForm D · SEC · 2nd filing$1.6M
- Private capital raisedForm D · SEC · 1st filing$942K
Show 6 earlier federal awards
- Federal grantHealth and Human S · Phase II · Small-molecule agonists of the RIG-I-like receptor pathway as cancer immunotherapeutics$1.5M
- Federal grantHealth and Human S · Phase I · Small-molecule agonists of the RIG-I-like receptor pathway as cancer immunotherapeutics$225K
- Federal grantHealth and Human S · Phase I · Development of an alpha-conotoxin RgIA analog as a novel, non-opioid therapeutic for chronic neuropathic pain$225K
- Federal grantHealth and Human S · Phase II · Development of novel isoflavone drugs as broad spectrum antivirals$746K
- Federal grantHealth and Human S · Phase I · Therapeutic Potential of the Potassium Channel Inhibitor SHK-186 for Pediatric Lupus$225K
- Federal grantHealth and Human S · Phase II · Development of novel isoflavone drugs as broad spectrum antivirals$1.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#152 · top 30%
- Granted patents#35 · top 7%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Shawn IadonatoResearcherExecutive Officer, DirectorLinked by $1.5M in grants as PI
- Campion FellinExecutive OfficerNamed in SEC Form D filings
- Charles MagnessDirectorNamed in SEC Form D filings
- Craig PhilipsExecutive OfficerNamed in SEC Form D filings
- Don R. MerlinoDirectorNamed in SEC Form D filings
- Kenneth NorthExecutive OfficerNamed in SEC Form D filings
Show all 18 people
- Kevin OhDirectorNamed in SEC Form D filings
- Kyungwon R. OhDirectorNamed in SEC Form D filings
- Lucien Fouke IIIExecutive OfficerNamed in SEC Form D filings
- Marion R. FooteDirectorNamed in SEC Form D filings
- Michael BanksExecutive OfficerNamed in SEC Form D filings
- Pauline KennyExecutive OfficerNamed in SEC Form D filings
- Raymond R. BartoszekDirectorNamed in SEC Form D filings
- Richard R. SamuelsonDirectorNamed in SEC Form D filings
- Robert HedequistExecutive OfficerNamed in SEC Form D filings
- Shawn ladonatoExecutive Officer, DirectorNamed in SEC Form D filings
- Steven MitchellDirectorNamed in SEC Form D filings
- William CadwalladerExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 9 granted of 40- New patentAnti-vista Antibodies And Uses ThereofUSPTOUS 12,760,104
- PendingPurines And Methods Of Their UseUSPTOApplication 18717174
- PendingCompounds And Compositions That Inhibit PikfyveUSPTOApplication 18717144
Show all 40 patent records
- Anti-vista Antibodies And Uses ThereofOct 13, 2026 · US 12,760,104Granted
- Purines And Methods Of Their UseNov 20, 2025 · Application 18717174Pending
- Compounds And Compositions That Inhibit PikfyveNov 20, 2025 · Application 18717144Pending
- Pyridopyrimidines And Methods Of Their UseSep 18, 2025 · Application 18717167Pending
- Pyrimidines And Methods Of Their UseJun 19, 2025 · Application 18717141Pending
- Proteasome Activity Enhancing CompoundsJun 3, 2025 · US 12,319,698Granted
- Bicyclic Heteroarenes And Methods Of Their UseMay 8, 2025 · Application 18717172Pending
- Proteostasis RegulatorsDec 31, 2024 · US 12,180,189Granted
- Pyridopyrimidines And Methods Of Their UseJun 27, 2024 · Application 18007807Pending
- Purines And Methods Of Their UseMay 9, 2024 · Application 18007983Pending
- Anti-vista Antibodies And Uses ThereofApr 25, 2024 · Application 18276417Pending
- Proteasome Activity Enhancing CompoundsApr 16, 2024 · US 11,958,873Granted
- Proteasome Activity Enhancing CompoundsApr 11, 2024 · Application 18351264Pending
- Compositions And Methods For The Treatment And Prevention Of Neurological DisordersJan 18, 2024 · Application 18007788Pending
- Amino Alcohol Compounds And Uses ThereofOct 26, 2023 · Application 18007812Pending
- Bicyclic Heteroarenes And Methods Of Their UseAug 31, 2023 · Application 18007797Pending
- Modifications And Uses Of Conotoxin PeptidesApr 4, 2023 · US 11,618,772Granted
- Compositions And Methods For The Treatment And Prevention Of Neurological DisordersApr 14, 2022 · Application 17560872Pending
- Anti-viral Compounds, Pharmaceutical Compositions, And Methods Of Use ThereofAug 27, 2020 · Application 16870208Pending
- Anti-viral Compounds, Pharmaceutical Compositions, And Methods Of Use ThereofJan 3, 2019 · Application 15885333Pending
- Anti-viral CompoundsMay 1, 2018 · US 9,956,285Granted
- Anti-viral Compounds, Pharmaceutical Compositions, And Methods Of Use ThereofFeb 6, 2018 · US 9,884,876Granted
- Anti-viral CompoundsJan 31, 2017 · US 9,555,106Granted
- Anti-viral Compounds, Pharmaceutical Compositions And Methods Of Use ThereofMay 5, 2016 · Application 14895899Pending
- Anti-viral CompoundsApr 14, 2016 · Application 14957507Pending
- Anti-viral CompoundsDec 3, 2015 · Application 14733443Pending
- Anti-viral CompoundsJul 7, 2015 · US 9,073,946Granted
- Anti-viral CompoundsAug 14, 2014 · Application 14348520Pending
- Activators Of The Retinoic Acid Inducible Gene "RIG-1" Pathway And Methods Of Use ThereofApplication PCTUS2019045824Pending
- Activators Of The Retinoic Acid Inducible Gene "RIG-1" Pathway And Methods Of Use ThereofApplication PCTUS2019045823Pending
- Activators Of The Retinoic Acid Inducible Gene "rig-i' Pathway And Methods Of Use ThereofApplication PCTUS2018000283Pending
- Activators of the retinoic acid inducible gene "RIG-I" pathway and methods of use thereofApplication 62764944Pending
- Activators Of The Retinoic Acid Inducible Gene "rig-i" Pathway And Methods Of Use ThereofApplication 62716830Pending
- Anti-vista Antibodies And Uses ThereofApplication PCTUS2022016912Pending
- Compounds And Compositions That Inhibit PikfyveApplication PCTUS2022052130Pending
- Purines And Methods Of Their UseApplication PCTUS2022052118Pending
- Bicyclic Heteroarenes And Methods Of Their UseApplication PCTUS2022052261Pending
- Pyridopyrimidines And Methods Of Their UseApplication PCTUS2022052206Pending
- Anti-viral Compounds, Pharmaceutical Compositions, And Methods Of Use ThereofApplication PCTUS2015059611Pending
- Anti-viral Compounds, Pharmaceutical Compositions, And Methods Of Use ThereofApplication PCTUS2015054250Pending
Related companies, and why
- Neogene TherapeuticsSimilar federal contract value in Biotech · null in contracts
- VBI VACCINES INC.Similar federal contract value in Biotech · null in contracts
- ROTATION MEDICAL INCSimilar federal contract value in Biotech · null in contracts
- JuvoBio Pharmaceuticals Inc.Similar federal contract value in Biotech · null in contracts
- ReplimuneSimilar federal contract value in Biotech · null in contracts
- Certara, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .